NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,144,443 | -24.4% | 1,048,098 | +0.0% | 0.01% | -28.6% |
| Q2 2023 | $26,636,246 | -29.9% | 1,047,846 | -0.3% | 0.01% | -36.4% |
| Q1 2023 | $37,986,745 | -8.0% | 1,050,809 | +0.8% | 0.01% | -8.3% |
| Q4 2022 | $41,270,169 | -15.2% | 1,042,176 | -0.2% | 0.01% | -25.0% |
| Q3 2022 | $48,659,000 | +6.4% | 1,044,181 | +0.1% | 0.02% | +14.3% |
| Q2 2022 | $45,713,000 | -39.3% | 1,042,954 | +0.2% | 0.01% | -26.3% |
| Q1 2022 | $75,293,000 | -10.2% | 1,040,973 | +0.6% | 0.02% | -5.0% |
| Q4 2021 | $83,879,000 | -48.9% | 1,034,650 | -26.6% | 0.02% | -52.4% |
| Q3 2021 | $164,123,000 | -30.2% | 1,410,242 | -0.6% | 0.04% | -27.6% |
| Q2 2021 | $235,272,000 | +19.5% | 1,419,094 | +0.6% | 0.06% | +9.4% |
| Q1 2021 | $196,873,000 | -22.1% | 1,411,275 | -3.3% | 0.05% | -28.4% |
| Q4 2020 | $252,566,000 | +24.7% | 1,459,074 | +0.4% | 0.07% | +8.8% |
| Q3 2020 | $202,461,000 | +15.6% | 1,453,415 | -0.9% | 0.07% | +7.9% |
| Q2 2020 | $175,182,000 | +23.5% | 1,466,330 | +3.3% | 0.06% | +5.0% |
| Q1 2020 | $141,891,000 | -17.3% | 1,419,187 | -2.8% | 0.06% | +13.2% |
| Q4 2019 | $171,547,000 | +0.5% | 1,459,483 | -26.5% | 0.05% | +17.8% |
| Q3 2019 | $170,625,000 | +33.5% | 1,984,709 | +0.7% | 0.04% | +36.4% |
| Q2 2019 | $127,778,000 | +331.7% | 1,970,969 | +316.2% | 0.03% | +230.0% |
| Q1 2019 | $29,600,000 | +61.8% | 473,514 | +0.7% | 0.01% | +42.9% |
| Q4 2018 | $18,290,000 | -30.8% | 470,281 | +1.4% | 0.01% | -12.5% |
| Q3 2018 | $26,432,000 | -53.2% | 463,718 | -34.4% | 0.01% | -57.9% |
| Q2 2018 | $56,434,000 | -8.8% | 706,750 | -1.0% | 0.02% | -17.4% |
| Q1 2018 | $61,874,000 | +27.2% | 713,903 | +1.3% | 0.02% | +27.8% |
| Q4 2017 | $48,639,000 | -35.8% | 704,512 | -15.5% | 0.02% | -35.7% |
| Q3 2017 | $75,794,000 | +21.4% | 833,987 | -0.6% | 0.03% | +47.4% |
| Q2 2017 | $62,423,000 | -20.0% | 838,672 | +0.8% | 0.02% | -26.9% |
| Q1 2017 | $77,981,000 | +23.6% | 832,234 | -4.1% | 0.03% | +23.8% |
| Q4 2016 | $63,078,000 | +95.4% | 868,131 | +180.8% | 0.02% | +90.9% |
| Q3 2016 | $32,277,000 | +57537.5% | 309,207 | +29320.3% | 0.01% | – |
| Q2 2015 | $56,000 | – | 1,051 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |